

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <b>GELLERFORS2</b>
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/048234</b>
INTERNATIONAL APPLICATION NO. <b>PCT/DK00/00425</b>	INTERNATIONAL FILING DATE <b>27 July 2000</b>	PRIORITY CLAIMED <b>27 July 1999</b>
TITLE OF INVENTION <b>PRODUCTION FOR rhPBGD AND NEW THERAPEUTIC METHODS FOR ...</b>		
APPLICANT(S) FOR DO/EO/US <b>P. GELLERFORS et al.</b>		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
- ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
- ☒ The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31).
- ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - ☐ is attached hereto (required only if not transmitted by the International Bureau).
  - ☒ has been communicated by the International Bureau.
  - ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
- ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - ☒ have been communicated by the International Bureau.
  - ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - ☐ have not been made and will not be made.
- ☒ A copy of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

- ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- ☐ An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- ☒ A **FIRST** preliminary amendment.
- ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
- ☐ A substitute specification.
- ☐ A change of power of attorney and/or address letter.
- ☒ Other items or information:
  - ☒ Courtesy copy of the International Application as filed.
  - ☒ Courtesy copy of the first page of the International Publication (WO 01/07065).
  - ☒ Courtesy copy of the **International Preliminary Examination Report with annexes containing pages 8, 9, 103, 112, 119, 120, 126, 127 and 129-131 to be substituted for original specification pages 8, 9, 103, 112, 119, 120, 126, 127 and 129-131 and claims 1-11 to be substituted for original claims 1-57 and drawing sheets 38/49-49/49 to be substituted for original sheets 38/49-49/49 for examination in this case.**
  - ☒ Drawings, 49 sheets, Figures 1-49.
  - ☒ Courtesy Copy of the International Search Report.
  - ☐ Applicant claims small entity status. See 37 CFR 1.27.
  - ☒ The application is (or will be) assigned to: HEMEBIOTECH A/S, whose address is 12 C, DK-3400 Hillerød, Denmark.

